Moreover, Apt-HJ significantly improved the anticancer efficacy in tumor-bearing mice vs. free PD-L1 aptamers (Figure 8), indicating that Apt-HJ might be better suited for in vivo ICB therapies. The gene discussed is CD274; the disease is neoplasm.